Macrolide Antibiotics

Increased risk of Torsade de Pointes. Avoid concomitant use.

Strong CYP3A4 inhibitors should be avoided with bromocriptine. Ensure adequate washout before initiating bromocriptine treatment.

Parenteral bumetanide with aminoglycosides should be avoided except in life-threatening conditions, especially with impaired renal function, due to ototoxic potential.

CYP 3A4 inhibitors increase dihydroergotamine exposure; contraindicated per prescribing information.

Contraindicated due to potential risk of torsade de pointes-type ventricular tachycardia when prolonging QT interval.

CYP 3A4 inhibitors that elevate ergotamine blood levels and are associated with vasospastic reactions; contraindicated.

Contraindicated per CONTRAINDICATIONS and WARNINGS. Macrolide antibiotics elevate blood levels of ergotamine and have been reported to cause vasospastic reactions.

Furosemide may increase ototoxic potential of aminoglycosides, especially with impaired renal function. Avoid this combination except in life-threatening situations.

Patients receiving antibiotics generally should not be treated with Mecamylamine HCl (ganglion blocker).

Use of macrolide antibiotics in patients with prolonged QT intervals has been rarely associated with ventricular arrhythmias. Concomitant administration should not be undertaken.

Macrolide antibiotics cause significant decrease in corticosteroid clearance, potentially increasing corticosteroid effects.

Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.

Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.

Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics.

Macrolide antibiotics cause significant decrease in corticosteroid clearance, increasing corticosteroid levels.

Ethacrynate sodium may increase ototoxic potential of aminoglycosides. Concurrent use should be avoided.

Ethacrynic acid may increase the ototoxic potential of aminoglycoside antibiotics; concurrent use should be avoided.

Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function. Avoid combination except in life-threatening situations.

Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function. Avoid this combination except in life-threatening situations.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Oral quinolone antibiotics may have reduced absorption when co-administered with lanthanum carbonate. Separate dosing by at least 1 hour before or 4 hours after.

Oral or intravenous sulfonamides may increase methotrexate plasma concentrations and are highly protein-bound, increasing risk of severe adverse reactions.

Sulfonamide antibiotics may increase methotrexate plasma concentrations, increasing risk of severe adverse reactions.

Concomitant use may add to QT prolongation effects and increase risk of cardiac arrhythmia. Avoid combination.

CYP 3A4 inhibitors that may decrease metabolism of corticosteroids, increasing risk of side effects.

Should be used cautiously or avoided during pyridostigmine treatment due to interference with neuromuscular transmission.

Loop diuretics increase ototoxic potential; avoid concomitant use with torsemide if possible.

CYP3A4 inhibitors that increase tramadol plasma concentration and M1 levels, increasing risk of seizures, serotonin syndrome, and potentially fatal respiratory depression.

Macrolide antibiotics cause significant decrease in corticosteroid clearance, increasing corticosteroid levels.

Zinc can inhibit the absorption of certain antibiotics; take at least 2 hours apart to minimize interactions.

Moderate CYP1A2 inhibitors; should be avoided unless clinically necessary due to potential for increased alosetron exposure.

Moderate CYP1A2 inhibitors. Concomitant administration with alosetron should be avoided unless clinically necessary due to potential drug interactions.

Increased risk of methemoglobinemia when concurrently exposed to antibiotics.

May prolong neuromuscular blockade action of cisatracurium besylate. Use peripheral nerve stimulator and monitor clinical signs.

Potent CYP3A4 inhibitors expected to decrease clearance of citalopram.

May cause significant decrease in dexamethasone clearance.

Macrolide antibiotics cause significant decrease in dexamethasone clearance, increasing corticosteroid levels.

Macrolide antibiotics cause significant decrease in dexamethasone clearance.

Carbapenem antibiotics may affect valproate clearance. Monitoring of valproate concentrations is recommended.

Zinc can inhibit the absorption of certain antibiotics; take at least 2 hours apart to minimize interactions.

Some macrolide antibiotics are significant CYP3A inhibitors; estazolam should be used with caution and appropriate dosage reduction may be needed.

May potentiate hypoglycemic action of glyburide resulting in severe hypoglycemia.

May increase the glucose-lowering effect of glipizide, increasing susceptibility to hypoglycemia. Monitor closely.

Macrolide antibiotics significantly decrease corticosteroid clearance, increasing corticosteroid levels.

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia; dosage reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia; dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.

Macrolide antibiotics cause a significant decrease in corticosteroid clearance.

Macrolide antibiotics cause significant decrease in corticosteroid clearance with methylprednisolone acetate.

Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.

Reports of pregnancy with hormonal contraceptives and antibiotics exist, though clinical studies show inconsistent effects on steroid concentrations.

Macrolide antibiotics cause significant decrease in corticosteroid clearance, increasing corticosteroid effects.

Increased risk of methemoglobinemia when concurrently exposed.

Macrolide antibiotics cause significant decrease in corticosteroid clearance, increasing corticosteroid levels.

Macrolide antibiotics cause a significant decrease in corticosteroid clearance.

SUFLAVE can reduce absorption of fluoroquinolone antibiotics. Administer at least 2 hours before and not less than 6 hours after SUFLAVE to avoid chelation with magnesium.

SYMLIN may delay absorption of oral antibiotics. Administer at least 1 hour prior to or 2 hours after SYMLIN injection.

Macrolide antibiotics cause significant decrease in corticosteroid clearance, potentially increasing prednisone levels.

May decrease the absorption of vitamin B12.

Zinc can inhibit absorption of certain antibiotics; separate administration by at least 2 hours to minimize interaction.

Reduced absorption of fluoroquinolone antibiotics due to chelation with magnesium. Administer at least 2 hours before and not less than 6 hours after CLENPIQ.

Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution can reduce absorption of fluoroquinolone antibiotics via chelation with magnesium. Administer at least 2 hours before and not less than 6 hours after this product.

Reduced absorption due to chelation with magnesium. Administer at least 2 hours before and not less than 6 hours after SUTAB.

Administer at least 2 hours before and not less than 6 hours after SUPREP to avoid chelation with magnesium and reduced absorption.

Sucralfate reduces the bioavailability of fluoroquinolone antibiotics. Dosing 2 hours before sucralfate eliminates the interaction.

Macrolide antibiotics cause a significant decrease in corticosteroid clearance.

Carbapenem antibiotics may affect valproate concentrations. Monitoring of valproate concentrations is recommended.

May affect valproate clearance. Monitoring of valproate concentrations recommended.

Zinc can inhibit the absorption of certain antibiotics; take at least 2 hours apart to minimize interactions.

Zinc can inhibit the absorption of certain antibiotics; take at least 2 hours apart to minimize interactions.

No clinically significant interactions noted with concomitant use, though caution advised pending wider clinical experience.

Reports of pregnancy while taking hormonal contraceptives and antibiotics, though clinical studies have not shown consistent effects on plasma concentrations.

Clinical studies of interactions with antibiotics have not been conducted; potential interaction unknown.